
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is poised for continued success, with a strong portfolio of flagship drugs, including red blood cell boosters and immune system boosters, as well as a growing oncology and biosimilars franchise, and recent acquisitions adding further potential for growth. Their current pipeline and key catalysts, such as their Lp(a) program and phase 3 Sjogren's data, also provide opportunities for future growth. Strong commercial performance, as seen in their recent Rx data and continued growth in key products like Repatha, supports a positive outlook for Amgen's stock. However, potential risks, such as competition in the obesity market or biosimilar erosion of key products, should also be considered.
Bears say
Amgen is facing several potential risks, such as delays or setbacks in competitors' obesity programs, competition for its bone-strengthening drugs from biosimilars, and negative tax decisions in ongoing litigation with the IRS, that could impact its future earnings and overall growth. Even though there is room for speculation about its latest drug data, Amgen has been positioned as a leader in leveraging Repatha for the niche drug market and is expected to see positive tailwinds from the trajectory of positive class data. With an estimated 75% probability of success for its drug olpasiran, peak sales of $4.4 billion are anticipated, mainly driven by its use in secondary prevention for patients with established ASCVD.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares